MicroRNA-30 and 145 as Targets for the Treatment of Cardiovascular Diseases: Therapeutic Feasibility and Challenges

Title:MicroRNA-30 and 145 as Targets for the Treatment of Cardiovascular Diseases: Therapeutic Feasibility and Challenges

Volume: 27 Issue: 37

Author(s): Sara E.L. Tolouei, Tatiana Z. Curi, Lislaine M. Klider and Arquimedes G. Junior*

Affiliation:

• Laboratory of Reproductive Toxicology, Department of Pharmacology, Federal University of Paraná (UFPR), Curitiba, PR,Brazil

Keywords: Epigenetics, heart diseases, non-communicable disorders, RNA therapy, small non-coding RNAs, vascular diseases.

Abstract: Cardiovascular diseases (CVDs) are a group of non-communicable disorders of the heart and blood vessels. Although lifestyle changes as well as pharmacological treatments and surgical interventions are available in many countries, CVDs are still considered the number one cause of mortality worldwide. Hence, considering that most CVDs are caused by genetic and environmental imbalances, micro-RNAs (miRNAs or miRs) appear as a plausible therapeutic option for CVDs as they are able to regulate a wide number of genes due to multiple target sites in different genes. Since miRNA-30 and -145 have been shown to play critical roles in the cardiovascular system, acting as important regulators of many functions and biological processes, this review focuses on summarizing recent findings on their involvement in CVDs, mainly as targets for therapeutic intervention. Therefore, the biology, mechanisms of action and data on what has been discovered so far regarding miRNA-30 and 145 as therapeutic targets for CVDs are presented.

Cite this article as:

Tolouei E.L. Sara , Curi Z. Tatiana , Klider M. Lislaine and Junior G. Arquimedes *, MicroRNA-30 and 145 as Targets for the Treatment of Cardiovascular Diseases: Therapeutic Feasibility and Challenges, Current Pharmaceutical Design 2021; 27 (37) . https://dx.doi.org/10.2174/1381612826666201211120822